List of phase III cancer clinical trials 2014
compound |
cancer type |
reference |
companies involved |
|---|---|---|---|
Imprime |
colorectal cancer |
||
Lonsurf (trifluridine and tipiracil hydrochloride) |
colorectal cancer |
Taiho Pharmaceuticals |
|
Obinutuzumab |
chronic lymphocytic leukemia |
Roche |
|
Galeterone |
prostate cancer |
Tokai Pharmaceuticals |
|
momelotinib |
myelofibrosis |
||
anastrozole |
breast cancer |
||
sapacitabine |
acute myeloid leukaemia |
||
everolimus |
breast cancer |
||
lenalidomide |
blood cancer |
Celgene |
|
asparaginase erythrocyte encapsulated |
Acute lymphoblastic leukemia |
||
Binimetinib |
melanoma |
||
ruxolitinib |
pancreatic cancer |
||
rindopepimut |
glioblastoma |
||
brentuximab |
Hodgkin's lymphoma |
||
crizotinib |
non-small-cell lung carcinoma |
||
Multikine |
head and neck cancer |
||
AZD9291 |
Non-small-cell lung carcinoma |
AURA2, AURA3 |
Astrazeneca |
panobinostat |
myeloma |
Novartis |
|
Algenpantucel-L |
pancreatic cancer |
IMPRESS |
NewLink pharmaceuticals |
Livatag |
hepatocellular carcinoma |
Onxeo |
|
bavituximab |
non-small cell lung cancer |
Bristol-Myers Squibb |
|
rilotumumab |
gastric cancer |
Amgen |
|
MPDL3280A |
lung cancer and bladder cancer |
||
cidofovir |
cervical cancer |
||
leucovorin |
pancreatic cancer |
||
rociletinib |
Non-small-cell lung carcinoma |
TIGER |
Clovis Oncology |
DCVax-L |
gliobastoma |
||
gefitinib |
esophageal cancer |
||
Zoptarelin |
endometrial cancer |
||
Ganetespib |
lung cancer |
||
nivolumab |
melanoma cancer |
||
avastin |
ovarian cancer |
||
dacomitinib |
Non-small-cell lung carcinoma |
||
ipilimumab |
lung cancer |
||
Crizotinib |
lung cancer |
||
fosbretabulin |
ovarian cancer |
||
Evofosfamide |
blood cancer |
||
Tivantinib |
lung cancer |
||
afatinib |
lung cancer |
||
Daratumumab |
multiple myeloma |
||
trastuzumab |
breast cancer |
||
ofatumumab |
chronic lymphocytic leukaemia |
||
Eribulin |
non-small cell lung cancer |
||
REOLYSIN |
prostate cancer |
||
abraxane |
prostate cancer |
||
enzalutamide |
prostate cancer |
||
PV-10 |
melanoma |
||
neratinib |
breast cancer |
||
Elotuzumab and Nivolumab |
blood cancer |
||
ODM-201 |
prostate cancer |
||
Olaparib |
ovarian cancer |
||
Folfoxiri |
colorectal cancer |
||
Imbruvica |
chronic lymphocytic leukaemia |
||
Nintenadib |
mesothelioma |
||
Nintedanib |
colorectal cancer |
||
Xilonix |
colorectal cancer |
||
Bevacizumab |
ovarian cancer, breast cancer |
||
HA-itrinotecan |
metastatic colorectal cancer |
||
Anamorelin |
Cancer anorexia-cachexia syndrome (CACS)| Ref |
||
Palbociclib |
breast cancer |
||
Decapeptyl |
prostate cancer |
||
Aprepitant |
multiple myeloma |
||
Lenvatinib |
hepatocellular carcinoma |
||
Prostvac |
prostate cancer |
PROSPECT |
Bavarian Nordic |